Editas, Allergan kick off long-awaited in vivo CRISPR trial

At long last, Editas Medicine has made it. The gene-editing biotech and its partner, Allergan, are moving their treatment for a rare form of blindness into human testing. Though they are not the first companies to test a CRISPR-based medicine in humans—that distinction goes to CRISPR Therapeutics and Vertex Pharmaceuticals—their treatment is the first that edits DNA within the body.
Read more...

;